A Phase 3, Randomized, Double-blind, Study Evaluating Efficacy and Safety of Riliprubart Versus Intravenous Immunoglobulin (IVIg) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy

Summary

The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  riliprubart

  Pharmaceutical form: Solution Route of administration: IV solution

• Drug
  Placebo

  Pharmaceutical form: Solution Route of administration: IV solution

• Drug
  riliprubart

  Pharmaceutical form: Solution Route of administration: SC solution

• Drug
  Placebo

  Pharmaceutical form: Solution Route of administration: SC solution

• Drug
  IVIg

  Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution

• Drug
  Placebo

  Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution

Locations (118)